FDA Clears New Alzheimer's Drug Amid Lingering Controversy
The U.S. Food and Drug Administration on Friday approved Eisai and Biogen's new Alzheimer's treatment Leqembi via the agency's accelerated approval program, which has recently come under fire from the public...To view the full article, register now.
Already a subscriber? Click here to view full article